Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders

C Eckerström; J Svensson; P Kettunen; M Jonsson; M Eckerström

doi:10.1002/dad2.12031

Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders

Alzheimers Dement (Amst). 2021 Apr 1;13(1):e12031. doi: 10.1002/dad2.12031. eCollection 2021.

Authors

C Eckerström^{1

2}, J Svensson³, P Kettunen¹, M Jonsson¹, M Eckerström¹

Affiliations

¹ Department of Psychiatry and Neurochemistry Sahlgrenska Academy Institute of Neuroscience and Physiology University of Gothenburg Sweden.
² Department of Immunology and Transfusion Medicine Region Västra Götaland Sahlgrenska University Hospital Sweden.
³ Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy University of Gothenburg Sweden.

Abstract

Introduction: To evaluate the usefulness of the 2018 NIA-AA (National Institute on Aging and Alzheimer's Association) research framework in a longitudinal memory clinic study with different clinical outcomes and underlying disorders.

Methods: We included 420 patients with mild cognitive impairment or subjective cognitive impairment. During the follow up, 27% of the patients converted to dementia, with the majority converting to Alzheimer's disease (AD) or mixed dementia. Based on the baseline values of the cerebrospinal fluid biomarkers, the patients were classified into one of the eight possible ATN groups (amyloid beta [Aβ] aggregation [A], tau aggregation reflecting neurofibrillary tangles [T], and neurodegeneration [N]).

Results: The majority of the patients converting to AD and mixed dementia were in ATN groups positive for A (71%). The A+T+N+ group was highly overrepresented among converters to AD and mixed dementia. Patients converting to dementias other than AD or mixed dementia were evenly distributed across the ATN groups.

Discussion: Our findings provide support for the usefulness of the ATN system to detect incipient AD or mixed dementia.

Keywords: Alzheimer's disease; Lewy body dementia; cerebrospinal fluid biomarkers; dementia; diagnosis; frontotemporal dementia; mild cognitive impairment; mixed dementia; subcortical vascular dementia.